Accelovance Welcomes Robert C. deGroof, Ph.D. as Chief Scientific Officer

    ROCKVILLE, Md., May 3 /PRNewswire/ -- Accelovance, a Rockville,
 Maryland based clinical services company is pleased to name Robert C.
 deGroof, Ph.D. as Chief Scientific Officer. In this role, Dr. deGroof will
 bring his 25 years of pharmaceutical industry experience to lead all
 clinical and regulatory services for current and upcoming research studies.
     "We are excited to have Bob formally join us from his previous
 consultant role. His experience with pharma and biotech will help position
 our company to deliver a higher level of service to our clients and
 strengthen our core competencies. This addition is an integral step in
 moving Accelovance into its next phase of growth," remarked Stephen J.
 Trevisan, CEO and President of Accelovance.
     Before arriving at Accelovance, Dr. deGroof served as Senior Vice
 President of Drug Development for Ambit Biosciences where he managed
 clinical, toxicology, manufacturing, quality assurance and regulatory
 affairs for all of their products. He had similar responsibilities as the
 Senior Vice President of Scientific Affairs at Alteon Inc. Prior to Alteon,
 Inc., he held leadership positions in drug development and regulatory
 affairs at Johnson and Johnson and Bristol-Myers Squibb. Additionally, for
 more than 10 years Dr. deGroof operated an independent consultancy for
 strategic development of prescription and non-prescription pharmaceuticals.
 Dr. deGroof held academic appointments at the medical schools of the
 University of Pennsylvania and Thomas Jefferson University. He holds a
 Ph.D. in Physiology and Pharmacology from Duke University and a B.S. in
 Electrical Engineering from the University of Florida.
     "It is exciting to join an entrepreneurial and client focused company
 like Accelovance. My goal is to help deliver on our client's needs and
 expand our service offerings over time," commented Dr. deGroof on his new
 role.
     Headquartered in Rockville, Maryland, Accelovance is a privately held
 company that has developed a unique system for delivering quality, on time,
 and cost effective clinical studies. In China, the Company operates through
 its wholly-owned foreign enterprise in Beijing as a contract research
 organization (CRO). Accelovance is focused on optimizing the quality and
 productivity of multiple clinical sites, through strong central management
 and targeted pro-active patient recruitment. Delivering high quality and
 timely clinical trial support services, Accelovance is committed to
 understanding and meeting its clients needs to contribute to their success.
     For more information, visit the company's website at
 http://www.accelovance.com.
     CONTACT: Media: Garrett D. Smith at 240.238.4914
 
 

SOURCE Accelovance